CSOWM EXAM QUESTIONS AND
ANSWERS 2026 VERIFIED.
Management of BMI >/= 25 - ANS Diet, Exercise, Behavior
Management of BMI >/=30 - ANS Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + comorbidity - ANS Diet, exercise, behavior + pharmacotherapy
Management of BMI >/=35 + cormorbidity - ANS Bariatric surgery
Management of BMI >/=40 - ANS Bariatric surgery
Co-morbidities - ANS T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment - ANS Every month x3 months, then every 3 months
@COPYRIGHT ALL RIGHTS RESERVED PAGE 1 OF 27
,Effective weight loss % - ANS >/=5% in 3 months
Avoid these wt loss meds with HTN/HD - ANS Sympathomimetics
(phentermine/diethylproprion)
Avoid these wt loss medications with CVD - ANS Sypathomimetics
T2DM treatment + medications to support weight loss - ANS GLP-1 analog (mitigates
associated weight gain due to insulin) or SGLT-2 inhibitors + metformin. If using insulin,
recommend basal instead of combo
Drugs that induce weight gain - ANS Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite - ANS CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
@COPYRIGHT ALL RIGHTS RESERVED PAGE 2 OF 27
, Liver- glucagon
GLP-1 - ANS Secreted in response to glucose and promotes insulin release from pancreas and
satiety
Ghrelin - ANS produced in the stomach, orexigenic
Leptin - ANS proportional to fat mass, anorexigenic
Inhibits appetite
PYY - ANS Ileum and colon, anorexigenic
CCK - ANS duodenum, anorexigenic
Insulin - ANS Pancreas, anorexigenic
Phentermine - ANS noradrenergic, dopaminergic sympathomimetic amine
Start with 7.5-15mg/d, increase only with no results
Do not prescribe for someone with hx of psych dz or substance abuse
Lorcaserin (Belviq) - ANS Seratonin agent, stimulates seratonin type 2 receptor
Brand name: Phentermine/Topiramate - ANS Qysemia
@COPYRIGHT ALL RIGHTS RESERVED PAGE 3 OF 27
ANSWERS 2026 VERIFIED.
Management of BMI >/= 25 - ANS Diet, Exercise, Behavior
Management of BMI >/=30 - ANS Diet, exercise, behavior + pharmacotherapy
Management of BMI >/= 27 + comorbidity - ANS Diet, exercise, behavior + pharmacotherapy
Management of BMI >/=35 + cormorbidity - ANS Bariatric surgery
Management of BMI >/=40 - ANS Bariatric surgery
Co-morbidities - ANS T2DM
HTN
OSA and other respiratory disorders
NAFLD
OA
lipid abnormalities
gastrointestinal disorders
heart disease
Medication assessment - ANS Every month x3 months, then every 3 months
@COPYRIGHT ALL RIGHTS RESERVED PAGE 1 OF 27
,Effective weight loss % - ANS >/=5% in 3 months
Avoid these wt loss meds with HTN/HD - ANS Sympathomimetics
(phentermine/diethylproprion)
Avoid these wt loss medications with CVD - ANS Sypathomimetics
T2DM treatment + medications to support weight loss - ANS GLP-1 analog (mitigates
associated weight gain due to insulin) or SGLT-2 inhibitors + metformin. If using insulin,
recommend basal instead of combo
Drugs that induce weight gain - ANS Tricyclic antidepressants (Amitriptyline)
oral contraceptives (Ortho Tri-Cyclen, Yaz)
antipsychotics (Risperidone)
anticonvulsants
glucocorticoids (cortisol)
sulfonyureas- ( Glimepiride, Glipizide)
glitazones (Actos)
B-blockers (Propranolol, Metoprolol, Atenolol)
Hormonal signals for appetite - ANS CCK- duodenum
K cells- duodenum and jejunum: gatric inhibitory polypeptide
PYY- ileum and colon
GLP-1 -ileum
Pancreas- Insulin
Adipose tissue: Leptin
@COPYRIGHT ALL RIGHTS RESERVED PAGE 2 OF 27
, Liver- glucagon
GLP-1 - ANS Secreted in response to glucose and promotes insulin release from pancreas and
satiety
Ghrelin - ANS produced in the stomach, orexigenic
Leptin - ANS proportional to fat mass, anorexigenic
Inhibits appetite
PYY - ANS Ileum and colon, anorexigenic
CCK - ANS duodenum, anorexigenic
Insulin - ANS Pancreas, anorexigenic
Phentermine - ANS noradrenergic, dopaminergic sympathomimetic amine
Start with 7.5-15mg/d, increase only with no results
Do not prescribe for someone with hx of psych dz or substance abuse
Lorcaserin (Belviq) - ANS Seratonin agent, stimulates seratonin type 2 receptor
Brand name: Phentermine/Topiramate - ANS Qysemia
@COPYRIGHT ALL RIGHTS RESERVED PAGE 3 OF 27
